一种包载核酸的金属有机框架纳米粒及其制备方法与应用
By constructing Zn2+-EGCG coordinated metal-organic framework nanoparticles, the cell burial-degradation-efflux pathway was activated, solving the problems of easy degradation and toxicity in traditional nucleic acid drug delivery, and achieving efficient clearance of AS plaques and improved vascular stability.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CENT SOUTH UNIV
- Filing Date
- 2023-07-17
- Publication Date
- 2026-07-17
AI Technical Summary
Existing AS treatments are ineffective at removing plaques, traditional nucleic acid drug delivery carriers are easily degraded and toxic, and there is a lack of non-surgical treatments that can simultaneously promote cell burial, degradation and efflux.
By coordinating Zn2+ with epigallocatechin gallate (EGCG), a nanometal-organic framework (EZC) was constructed to deliver the burial-promoting nucleic acid CpG ODN 1826. This activated the burial-degradation-efflux pathway, and CpG ODN 1826 promoted macrophage phagocytosis of apoptotic cells. Zn2+ activated autophagy and upregulated ABCA1 protein efflux of cholesterol through EGCG.
It achieves efficient and low-toxicity plaque clearance, reduces circulating lipid levels, decreases vascular plaque burden, and promotes the conversion of macrophages from M1 to M2, providing a potential strategy for non-surgical treatment of AS.
Smart Images
Figure CN117045817B_ABST